<DOC>
	<DOC>NCT01155063</DOC>
	<brief_summary>Evaluating the safety, tolerability and efficacy of Aromasin® when used in routine clinical practice, evaluating adherence to prescribed Aromasin® treatment and to understand reasons for early discontinuation.</brief_summary>
	<brief_title>Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients</brief_title>
	<detailed_description>This study was terminated on 01-Aug-2011 due to very low potential to enroll planned number of patients or any sufficient number of patients for complete statistical analyses. This study is not being terminated because of safety or efficacy concerns.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Postmenopausal females. Patients who have had surgical treatment for histological confirmed breast cancer that was nonmetastatic at the time of the initial diagnosis. Patients who are diseasefree after 2 or 3 years of adjuvant tamoxifen treatment. Patients whose tumour was estrogen receptor positive (ER+). Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Patients for whom Aromasin® treatment is contraindicated (see SPC). Presence of metastasis or a contra lateral tumour. Other adjuvant endocrine therapy. Another concomitant antineoplastic treatment. Participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Exemestane</keyword>
	<keyword>Adjuvant Treatment In Postmenopausal Women</keyword>
	<keyword>Estrogen Receptor Positive Early Breast Cancer</keyword>
	<keyword>Tamoxifen</keyword>
</DOC>